InvestorsHub Logo
Followers 466
Posts 26931
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Wednesday, 04/25/2007 7:35:36 AM

Wednesday, April 25, 2007 7:35:36 AM

Post# of 8
First Albany Capital said the upgrade of the biopharmaceutical company's stock is based on better-than-expected sales of angina drug Ranexa, sooner-than-expected publication of the MERLIN trial results, and planned reductions of operating expenses.

--The brokerage's new price target on the stock is $13. (Reporting by Ratul Ray Chaudhuri in Bangalore)


surf's up......crikey